Login / Signup

Successful Use of Bortezomib in an Adolescent with Refractory TTP.

Junaid Ahmad WaliBrian M QuigleyBeverly Schaefer
Published in: Case reports in hematology (2023)
With increasing early and upfront use of rituximab and caplacizumab in the modern management of immune-mediated thrombotic thrombocytopenic purpura (iTTP), the risk of refractory disease is expected to decline. However, despite the use of adequate initial therapy, a small subset of patients develop a refractory disease which is difficult to manage. Bortezomib has come to be known as a safe and effective treatment option for refractory iTTP, but its use in children is limited. Here, we describe the case of an adolescent patient with refractory iTTP who had a satisfactory and sustained response to the use of bortezomib.
Keyphrases
  • newly diagnosed
  • young adults
  • multiple myeloma
  • mental health
  • ejection fraction
  • cell therapy
  • peritoneal dialysis
  • chronic lymphocytic leukemia